I agree that this site is using cookies. You can find further informations here.
X
Vesikari, T.
102  results:
Search for persons X
?
1

The persistence of seroprotective levels of antibodies afte..:

Vesikari, T. ; Langley, J.M. ; Spaans, J.N....
Vaccine.  41 (2023)  24 - p. 3584-3588 , 2023
Link: https://doi.org/10.1016/..
 
?
2

Immunogenicity and safety of a quadrivalent meningococcal t..:

van der Vliet, D. ; Vesikari, T. ; Sandner, B....
Epidemiology and Infection.  149 (2021)  - p. , 2021
Link: https://doi.org/10.1017/..
 
?
3

Rotavirus capsid VP6 tubular and spherical nanostructures a..:

Malm, M ; Heinimäki, S ; Vesikari, T.
Clinical and Experimental Immunology.  189 (2017)  3 - p. 331-341 , 2017
Link: https://doi.org/10.1111/..
 
?
4

Rotavirus Vaccines and Vaccination:

, In: Viral Gastroenteritis,
Vesikari, T. - p. 301-328 , 2016
Link: https://doi.org/10.1016/..
 
?
5

Contributors:

, In: Viral Gastroenteritis,
Ajami, N.J. ; Angel, J. ; Angel, M.... - p. xv-xix , 2016
Link: https://doi.org/10.1016/..
 
?
6

Report of the Third European Expert Meeting on Rotavirus Va..:

Huppertz, HI ; Borte, M ; Schuster, V..
Vaccine.  32 (2014)  34 - p. 4243-4248 , 2014
Link: https://doi.org/10.1016/..
 
?
7

Norovirus Vaccine: One Step Closer:

Vesikari, T. ; Blazevic, V.
Journal of Infectious Diseases.  211 (2014)  6 - p. 853-855 , 2014
Link: https://doi.org/10.1093/..
 
?
8

High Serum Levels of Norovirus Genotype-Specific Blocking A..:

Malm, M. ; Uusi-Kerttula, H. ; Vesikari, T..
Journal of Infectious Diseases.  210 (2014)  11 - p. 1755-1762 , 2014
Link: https://doi.org/10.1093/..
 
?
9

Safety and Immunogenicity of a Vero Cell Culture-Derived Wh..:

van der Velden, M. V. W. ; Fritz, R. ; Pollabauer, E. M....
Journal of Infectious Diseases.  209 (2013)  1 - p. 12-23 , 2013
Link: https://doi.org/10.1093/..
 
?
10

Cross subclade immunity after one-year booster immunization..:

Vesikari, T. ; Karvonen, A. ; Montomoli, E...
International Journal of Infectious Diseases.  16 (2012)  - p. e316 , 2012
Link: https://doi.org/10.1016/..
 
?
11

Characterization and immunogenicity of norovirus capsid-der..:

Huhti, L. ; Tamminen, K. ; Vesikari, T..
Archives of Virology.  158 (2012)  5 - p. 933-942 , 2012
Link: https://doi.org/10.1007/..
 
?
12

Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine..:

Schmader, K. E. ; Levin, M. J. ; Gnann, J. W....
Clinical Infectious Diseases.  54 (2012)  7 - p. 922-928 , 2012
Link: https://doi.org/10.1093/..
 
?
13

Norovirus genotypes in endemic acute gastroenteritis of inf..:

PUUSTINEN, L. ; BLAZEVIC, V. ; HUHTI, L....
Epidemiology and Infection.  140 (2012)  2 - p. 268-275 , 2012
Link: https://www.jstor.org/st..
 
?
14

Prevalence of norovirus GII‐4 antibodies in Finnish childre:

Nurminen, K. ; Blazevic, V. ; Huhti, L....
Journal of Medical Virology.  83 (2011)  3 - p. 525-531 , 2011
Link: https://doi.org/10.1002/..
 
?
15

Immunogenicity, reactogenicity and safety of the human rota..:

Vesikari, T. ; Karvonen, A. ; Bouckenooghe, A....
Vaccine.  29 (2011)  11 - p. 2079-2084 , 2011
Link: https://doi.org/10.1016/..
 
1-15